메뉴 건너뛰기
Multiple Sclerosis Journal
Volumn 21, Issue 2, 2015, Pages 132-133
Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis: No
Author keywords

[No Author keywords available]
Indexed keywords

BETA INTERFERON; GLATIRAMER; BIOLOGICAL MARKER; IMMUNOLOGIC FACTOR;
EID: 84923114535     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514565415     Document Type: Note
Times cited : (7)
References (7)
  • 1
    • 65249154822 scopus 로고    scopus 로고
    • Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach
    • Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach. Ann Neurol. 2009 ; 65: 268-275
    • (2009) Ann Neurol , vol.65 , pp. 268-275
    • Sormani, M.P.1    Bonzano, L.2    Roccatagliata, L.3
  • 2
    • 46749147136 scopus 로고    scopus 로고
    • Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients
    • Río J, Rovira A, Tintoré M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler. 2008 ; 14: 479-484
    • (2008) Mult Scler , vol.14 , pp. 479-484
    • Río, J.1    Rovira, A.2    Tintoré, M.3
  • 3
    • 0032864616 scopus 로고    scopus 로고
    • Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo controlled study of interferon-β1a in relapsing-remitting multiple sclerosis
    • Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol. 1999 ; 46: 197-206
    • (1999) Ann Neurol , vol.46 , pp. 197-206
    • Li, D.K.1    Paty, D.W.2
  • 4
    • 4844223606 scopus 로고    scopus 로고
    • Defining interferon β response status in multiple sclerosis patients
    • Rudick R, Lee J, Simon J, et al. Defining interferon β response status in multiple sclerosis patients. Ann Neurol. 2004 ; 56: 548-555
    • (2004) Ann Neurol , vol.56 , pp. 548-555
    • Rudick, R.1    Lee, J.2    Simon, J.3
  • 5
    • 84895740228 scopus 로고    scopus 로고
    • Assessing treatment response to interferon-β: Is there a role for MRI?
    • Dobson R, Rudick RA, Turner B, et al. Assessing treatment response to interferon-β: Is there a role for MRI?. Neurology. 2014 ; 82: 248-254
    • (2014) Neurology , vol.82 , pp. 248-254
    • Dobson, R.1    Rudick, R.A.2    Turner, B.3
  • 6
    • 84873353587 scopus 로고    scopus 로고
    • Predictors of long-term outcome in multiple sclerosis patients treated with interferon β
    • Bermel R, You X, Foulds P, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Ann Neurol. 2013 ; 73: 95-103
    • (2013) Ann Neurol , vol.73 , pp. 95-103
    • Bermel, R.1    You, X.2    Foulds, P.3
  • 7
    • 84910112577 scopus 로고    scopus 로고
    • Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients
    • Río J, Rovira A, Tintoré M, et al. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. Mult Scler. 2014 ; 20: 1602-1608
    • (2014) Mult Scler , vol.20 , pp. 1602-1608
    • Río, J.1    Rovira, A.2    Tintoré, M.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.